Add To Watchlist
Share URL
Vertex Pharmaceuticals Incorporated
VRTX: NasdaqGSLowest reading is at 31 out of 100. All scores are out of 100.
In Short
About The Company
CEO
Dr. Reshma Kewalramani FASN, M.D.
Market Cap
126.58 Billion USD
Sector
Healthcare
Website
https://www.vrtx.comLast Update
14/10/2026, 13:04:02
Description
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Read More
Strongest readings
- ✔Altman-Z score of 12.72 sits above the distress range
- ✔Return on capital employed of 21.38% is above the market average of 10.00%
- ✔Financial health is strong (health score 89 out of 100)
- ✔Debt is low at 0.11 times equity
- ✔Share count has been falling at 0.32% per year
Weakest readings
- ✘Returns on capital have declined over five years (15.36% lower)
- ✘Revenue is growing at 11.66% per year while free cashflow is falling
- ✘The current price sits above estimated fair value (margin of safety -83.53%)
- ✘Earnings and cashflow growth is weak (growth score 31 out of 100)
- ✘Price-to-earnings of 28.1 is above the market average of 19.6
Key Figures
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Price / earnings (TTM) | 28.05x | 19.60x | |
| ✘ | Margin of safety (DCF) | -83.53% | 17.95% | |
| ✔ | Revenue growth (5y average) | 11.66% | 10.97% | |
| ✘ | Dividend yield (TTM) | 0.00% | 1.85% | |
| ✔ | Share count, per year | -0.32% | 0.00% | |
| ✔ | Return on capital employed | 21.38% | 10.00% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Valuation
41 / 100Priced above the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Price / earnings | 28.05x | 19.60x | |
| ✘ | Free cashflow yield | 3.09% | 4.70% | |
| Price / earnings growth | N/A | 1.50x | ||
| Price / book | 6.07x | — | ||
| ✘ | Margin of safety | -83.53% | 17.95% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Estimated intrinsic value of 79.94 USD is below the current price of 499.74 USD
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Estimated Fair Value: 176 USD ✘
Current Price: 485.2 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.
Growth
31 / 100Growing more slowly than the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Revenue growth | 11.66% | 10.97% | |
| ✘ | Earnings growth | 8.33% | 14.48% | |
| ✘ | Cashflow growth | -14.99% | 12.35% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Revenue growth has slowed this year (10.23% against a five year average of 11.66%)
- ✔Earnings growth has improved this year (22.42% against a five year average of 8.33%)
- ✔Free cashflow growth has improved this year
- ✘Revenue is growing at 11.66% per year while free cashflow is falling at 14.99% per year
Health
89 / 100Balance sheet covers its obligations.
Measured on Leverage and capital, Funding and liquidity, Earnings quality.
| Status | Metric | Value | Reading | Threshold |
|---|---|---|---|---|
| ✔ | Altman-Z score | 12.72 | 3.00 | |
| ✔ | Piotroski score | 7.00 | 5.00 | |
| ✔ | Debt / equity | 0.11x | 0.80x | |
| ✔ | Current ratio | 2.90x | 1.00x | |
| ✔ | Interest coverage | 350.11x | 2.50x | |
| ✔ | Free cashflow / debt | 1.57x | 0.15x | |
| ✔ | Debt / capital | 0.10x | 1.00x |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Management
58 / 100Returns on capital are at or above the market.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Return on equity | 21.18% | 15.00% | |
| ✔ | Return on capital employed | 21.38% | 10.00% | |
| Return on assets | 15.42% | — | ||
| Free cashflow return on capital | 14.66% | — | ||
| ✘ | Return on capital, 5y change | -15.36% | 0.00% | |
| ✔ | Share count, per year | -0.32% | 0.00% | |
| ✔ | Share count, recent | -0.94% | 0.00% | |
| ✘ | Realized buyback return | -64.39% | 0.00% | |
| ✔ | Goodwill erosion / equity | 0.00% | 2.00% | |
| Price volatility, 5 year | 29.26% | — |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Shares were repurchased while the value score was only 41 out of 100
Analysts
not enough data| Status | Metric | Value | Reading | Neutral |
|---|---|---|---|---|
| Analyst opinion score | N/A | 50 |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Financial History
Annual figures across the full reporting history we hold.
Market Peers
VRTX
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
See 35+ Years Annual ReportsOther Information
Company Name
Vertex Pharmaceuticals Incorporated
Currency
USD
Beta
0.32
Vol Avg
1250831
Ceo
Dr. Reshma Kewalramani FASN, M.D.
Cik
0000875320
Cusip
Exchange
NasdaqGS
Full Time Employees
6400
Industry
Biotechnology
Sector
Healthcare
Ipo Date
Address
50 Northern Avenue
City
Boston
State
MA
Country
United States
Zip
02210
Phone
617 341 6100
Analysis Last Updated
14/10/2026, 13:04:02
Financial data compiled from SEC EDGAR filings and Yahoo Finance.